The neurology of HTLV-1 infection

Practical Neurology

Volumn 9, Issue 1, 2009, Pages 16-26

  Cooper, Sarah A ^a   van der Loeff, Maarten Schim ^b   Taylor, Graham P ^c  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; HUMAN T CELL LEUKEMIA VIRUS INFECTION; NEUROLOGIC DISEASE; NEUROLOGY; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; VIROLOGY;

HTLV-I INFECTIONS; HUMANS; NERVOUS SYSTEM DISEASES; NEUROLOGY;

EID: 59149088518     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/jnnp.2008.167155     Document Type: Review

References (60)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415-19.
2. de The G, Bomford R. An HTLV-1 vaccine: why, how and for whom? AIDS Res Hum Retroviruses 1993;9:381-6.
3. Taylor GP, Bodéus M, Courtois F, et al. The seroepidemiology of Human T-lymphotropic viruses types I and II in Europe: A prospective study of pregnant women. J Acquir Immune Defic Syndr 2005;38:104-9.
4. Proietti FA, Cameiro-Proietti AB, Catalan-Soares BC, et al. Global epidemiology of HTLV-1 infection and associated diseases. Oncogene 2005;24:6058-68.
5. Van Dooren S, Salemi M, Vandamme AM. Dating the origin of the African human T-cell lymphotropic virus type-1 (HTLV-1) subtypes. Mol Biol Evol 2001;18:661-71.
6. Larsen O, Andersson S, da Silva Z, et al. Prevalences of HTLV-1 infection and associated risk determinants in a urban population in Guinea-Bissau, West Africa. J Acquir Immune Defic Syndr 2000; 25:157-63.
7. Morofuji-Hiratu M, Kaliyama W, Nakashuma K, et al. Prevalence of antibody to HTLV-1 in Okinawa, Japan after an interval of 9 years. Am J Epidemiol 1993;137:43-8.
8. The HTLV-1 European Research Network. Seroepidemiology of the human T-cell leukaemia/lymphoma viruses in Europe. J Acquir Immune Defic Syndr Hum Retrovirol 1996;14:68-77.
9. Verdonck K, Gondzález E, Van Dooren S, et al. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Inf Dis 2007;7:266-81.
10. Ades AE, Parker S, Walker J, et al. Human T-cell leukaemia/ lymphoma virus infection in pregnant women in the United Kingdom: population study. BMJ 2000;320:1497-501.
11. Tosswill JHC, Taylor GP, Tedder IRS, et al. HTLV-1-associated disease in England and Wales 1993-1997: a retrospective study of serology requests. BMJ 1999;320:611-12.
12. Lee HH, Weiss SH. Brown LS, et al. Patterns of HIV-1 and HTLV-1/11 in intravenous drug users from the middle atlantic and central regions of the USA. J Infect Dis 1990;162:347-52.
13. Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type 1 infection. Lancet 1999;353:1951-8.
14. Hino S, Doi H. Mechanisms of HTLV-1 transmission. In: HTLV-1 and the nervous system. In: Roman G, Vernant J-C, Osame M, eds. New York: Alan R Liss, 495-501.
15. Manns A, Wilks RJ, Murphy EL, et al. A prospective study of transmission by transfusion of HTLV-1 and risk factors associated with seroconversion. Int J Cancer 1992;51:886-91.
16. Montgomery RD. The epidemiology of myelopathy associated with human T-lymphotropic virus 1. Trans R Soc Trop Med Hyg 1993; 87:154-9.
17. Gonzalez-Perez MP, Muňoz-Juarez -, Cárdenas FC, et al. HTLV-1 infection in various recipients from the same donor. Transplantation 2003;75:1006-11.
18. Tortevoye P, Tuppin P, Carles G, et al. Comparative trends of seroprevalence and seroincidence rates of human T cell lymphotropic virus type 1 and human immunodeficiency virus 1 in pregnant women of various ethnic groups sharing the same environment in French Guiana. Am J Trop Med Hyg 2005;73:560-5.
19. Araujo AQC, Silva MTT. The HTLV-1 neurological complex. Lancet Neural 2006;5:1068-76.
20. Bangham CR. The immune control and cell to cell spread of human T-cell lymphotropic virus type 1. J Gen Virol 2003;84:3177-89.
21. Marcos LA, Terashima A, Dupont HL, et al. Strongyloides hyperinfection syndrome: an emerging global infectious disease. Trans R Soc Trop Med Hyg 2008; 102:314-18.
22. Marinho J, Galväo-Castro B, Rodrigues LC, et al. Increased risk of tuberculosis with human T-cell lymphotropic virus type 1 infection: a case-control study. J Acquir Immune Defic Syndr 2005; 40:625-8.
23. Mani KS, Mani AJ, Montgomery RD. A spastic paraparesis syndrome in South India. J Neurol Sci 1969;9:179-99.
24. Gessain A, Barin F, Vernant J-C, et al. Antibodies to human T-lymphotropic virus type-1 in patients with tropical spastic paraparesis. Lancet 1985;2:407-10.
25. Osame M, Usuku K, Izumo S, et al. HTLV-1 associated myelopathy, a new clinical entity. Lancet 1986;1:1031-2.
26. Roman GC, Navarro-Roman U. The discovery of HTLV-1 myelitis: 21 years later. Lancet Neurol 2007;6:104-5.
27. Umehara F, Osame M. Histological analysis of HAM/TSP pathogenesis. In: Sugamira K, Uchiyame T, Masao M, Kannagi M, eds. Two decades of adult T-cell leukaemia and HTLV-1 research. Tokyo, Japan: Scientific Societies Press, 2003:141-8.
28. Kubota R, Soldan SS, Martin R, et al. Selected cytotoxic T lymphocytes with high specification for HTLV-I in cerebrospinal fluid from a HAM/TSP patient. J Neurovirol 2002;8:53-7.
29. Garcia-Vallejo F, Dominguez MC, Tamayo O. Autoimmunity and molecular mimickry in tropical spastic paraparesis/HTLV-1-associated myelopathy. Braz J Med Bio Res 2005;38:241-50.
30. Bangham CR. The immune response to HTLV-1. Curr Opin Immunol 2000;12:397-402.
31. Ramirez E, Cartier L, Torres M, et al. Temporal dynamics of human T-cell lymphotropic virus type 1 tax mRNA and proviral DNA load in peripheral blood mononuclear cells of htlv-1-associated myelopathy patients. J Med Virol 2007;79:782-90.
32. Araujo AQ, Andrade-Filho AS, Castro-Costa CM, et al. HTLV-1 associated myelopathy/tropical spastic paraparesis in Brazil: a nationwide survey. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:536-41.
33. Olindo S, Cabre P, Lezin A, et al. Natural history of human T-cell lymphotropic virus type 1-associated myelopathy: a 14 year follow-up study. Arch Neurol 2006;63:1560-6.
34. Prima JR, Briles CR, Oliveira Mde F, et al. Infectious dermatitis and HTLV-1-associated myelopathy/tropical spastic paraparesis in childhood and adolescence. Clin Inf Dis 2005;41:535-41.
35. Gotuzzo E, Cabrera J, Deza L, et al. Clinical characteristics of patients in Peru with Human T-cell Lymphotropic virus Type I-associated tropical spastic paraparesis. Clin Inf Dis 2004;31:939-44.
36. Vernant JC, Maurs L, Gessain A, et al. Endemic tropical spastic paraparesis associated with HTLV-1 a clinical and epidemiological study of 25 cases. Ann Neurol 1987;21:123.
37. Araujo A, Alfonso CR, Schor D, et al. Clinical and demographic features of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Rio de Janeiro, Brazil. Acta Neurol Scand 1993; 88:59-62.
38. Bhigjee AI, Kelbe C, Haribhai MC, et al. Myelopathy associated with HTLV-1 in Natal, South Africa. A clinical and investigative study in 24 patients. Brain 1990;113:1307-20.
39. Bartholomew C, Cleghorn F, Jack N, et al. Human T-cell lymphotropic virus type-1-associated facial nerve palsy in Trinidad and Tobago. Ann Neurol 1997;41:806-9.
40. Cabre P, Smadja D, Cabié A, et al. HTLV-1 and HIV infections of the central nervous system in tropical areas. J Neurol Neurosurg Psych 2000;68:550-7.
41. World Health Organization. Report of the scientific group convened by the WHO regional office for the western Pacific, Kagoshima, Japan, 10-15 December 1988 - Human T-cell lymphotropic virus type 1, HTLV- 1. Wkly Epidemiol Rec 1989;49:382-3.
42. De Castro-Costa CM, Araujo AQ, Barreto MM, et al. Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-1-associated myelopathy. AIDS Res Hum Retroviruses 2006;22:931-5.
43. Kramer A, Maloney EM, Morgan O, et al. Risk factors and cofactors for human T-cell lymphotropic virus type 1 (HTLV-1) associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica. Am J Epidemiol 1995;142:1212-19.
44. Berini CA, Susana Pascuccio M, Bautista CT, et al. Comparison of four commercial screening assays for the diagnosis of HTLV types 1 and 2. J Virol Methods 2008;147:322-7.
45. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-1 provirus load in 202 HAM/TSP patients and 243 asymptomatic HTLV-1 carriers: high provirus load strongly predisposes to HAM/TSP. J Neurovirol 1998;4:586-93.
46. Moreno-Carvalho OA, Nascimento-Carvalho CM, Galvão-Castro B. HTIV-1 associated tropical spastic paraparesis. Cerebrospinal fluid evolutive aspects in 128 cases. Arq Neuropsiquiatr 1995;53:604-7.
47. Gessain A. Virological aspects of tropical spastic paraparesis/HTLV-1 -associated myelopathy and HTLV-1 infection. J Neurovirol 1996; 2:299-306.
48. Lezin A, Olindo S, Oliére S, et al. HTLV-1 proviral load in cerebrospinal fluid: a new criterion for the diagnosis of HTLV-1 -associated myelopathy/tropical spastic paraparesis? J Infect Dis 2005;191:1830-4.
49. Bagnato F, Butman JA, Mora CA, et al. Conventional magnetic resonance imaging features in patients with tropical spastic paraparesis. J Neurovirol 2005;11:525-34.
50. Morgan D., Caskey MF, Abbehusen C, et al. Brain magnetic resonance imaging white matter lesions are frequent in HTLV-1 carriers and do not discriminate from HAM/TSP. AIDS Res Hum Retroviruses 2007; 23:1499-504.
51. Umehara F, Nose H, Saito M, et al. Abnormalities of spinal magnetic resonance images implicate clinical variability in human T-cell lymphotropic virus type 1-associated myelopathy. J Neurovirol 2007;13:260-7.
52. Izumo S, Goto I, Itoyama Y, et al. Interferon-alpha is effective in HTLV-1 associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 1996;46:1016-21.
53. Arimura K, Nakagawa M, Izumo S, et al. Safety and efficacy of interferon-alpha in 167 patients with human T-cell lymphotropic virus type-1 associated myelopathy. J Neurovirol 2007;13:364-70.
54. Taylor GP. Goon P, Furukawa Y, et al. Zidovudine plus lamivudine in Human T-cell Lymphotropic Virus type-1 associated myelopathy: a randomized trial. Retrovirology 2006;3:63.
55. Croda MG, de Oliveira AC, Vergara MP, et al. Corticosteroid therapy in TSP/HAM patients: the results from a 10 year open cohort. J Neurol Sci 2008;269:133-7.
56. Matsuo H, Nakamura T, Tsujilhata M, et al. Plasmapheresis in the treatment of human T-cell lymphotropic virus type-1 associated myelopathy. Lancet 1988;2:1109.
57. Lezin A, Gillet N, Olindo S, et al. Histone deacetylase medicated transcriptional activation reduces proviral loads in HTLV-1 -associated myelopathy/tropical spastic paraparesis patients. Blood 2007; 110:3722-8.
58. Morgan OS, Rodgers-Johson P, Mora C, et al. HTLV-1 and polymyositis in Jamaica. Lancet 1989;2:1184-7.
59. Leite AC, Mendonca GA, Serpa MJ, et al. Neurological manifestations in HTLV-1-infected blood donors. J Neurol Sci 2003;214:49-56.
60. Silva MTT, Leite ACC, Alamy AH, et al. ALS syndrome in HTLV-1 infection. Neurology 2005;65:1332-3.